AI giants are pouring hundreds of billions into new health focused tools, and hospitals, insurers and drug makers are under pressure to show they can use that firepower to cut costs and ease staffing strains. That puts high quality healthcare stocks with strong balance sheets and solid execution in a sweet spot. This article highlights three of the strongest options from our curated healthcare shortlist.
The three healthcare stocks profiled below are just a small sample, and the full screen surfaced 35 more companies with equally compelling stories that are not covered here. To identify and analyze the highest conviction healthcare ideas right now, head straight into the Best Healthcare Stocks screener .
GeneDx Holdings (WGS)
Overview:GeneDx Holdings is a genomics company that provides whole exome and whole genome sequencing to help diagnose pediatric and rare diseases, alongside AI driven analysis platforms.
Operations:GeneDx generated about $423 million from segment adjustments and $31 million from Fabric Genomics and Legacy Sema4, almost entirely in the United States at $454 million.
Market Cap:US$2.0b
GeneDx Holdings matters for this Best Healthcare Stocks screen because its genomic tests and AI tools aim to turn complex DNA data into clear answers for frontline clinicians.
"Rapid long-term reimbursement gains from Medicaid and commercial payers are unlikely to be sustainable as government cost-containment efforts intensify. This increases the risk that reimbursement rates for advanced diagnostics will decline and directly pressure GeneDx's future revenue growth and gross margins."
What ultimately happens to GeneDx's earnings power may hinge on how one quiet shift in payer behavior plays out over the next few years.
That quiet payer shift is exactly where the story gets interesting, and the full narrative for GeneDx Holdings lays out how GeneDx could turn reimbursement pressure into accelerating leverage.
iRhythm Holdings (IRTC)
Overview:iRhythm Holdings provides prescription remote cardiac monitoring services built around its Zio patch and software suite to detect arrhythmias.
Operations:iRhythm generates about US$825 million in revenue from surgical and medical equipment, entirely from customers in the United States.
Market Cap:US$3.4b
iRhythm Holdings matters for this Best Healthcare Stocks screen because Zio turns a simple wearable sensor into a continuous ECG monitoring service that plugs directly into day to day clinical workflows.
"Although the shift of arrhythmia detection into primary care and integrated delivery networks is widening the potential user base for Zio and supporting volume driven revenue, dependence on primary care workflows and EHR connectivity could expose the company to slower adoption or integration delays that weigh on growth and selling efficiency."
What happens to iRhythm's margins and revenue momentum may come down to how one behind the scenes integration bottleneck gets resolved.
That integration bottleneck is exactly where the real opportunity may sit, and the full narrative for iRhythm Holdings shows how iRhythm could turn workflow friction into accelerating scale.
Immunocore Holdings (IMCR)
Overview:Immunocore Holdings develops and commercializes T cell based immunotherapies like KIMMTRAK for cancers, infectious diseases, and autoimmune conditions, anchoring it firmly in biotech and life sciences.
Operations:Immunocore generates about $431 million from immunotherapies, with roughly $279 million from the United States and $134 million from Europe.
Market Cap:US$1.5b
Immunocore Holdings matters for the Best Healthcare Stocks screen because its marketed KIMMTRAK franchise and late stage melanoma programs tie directly into oncology immunotherapy, where real clinical outcomes and a deep pipeline can influence long term value.
"Enrollment in the Phase 3 TEBE-AM trial in previously treated advanced cutaneous melanoma is nearing the target of 540 patients, with top line data expected as early as the end of 2026."
The evolution of Immunocore's valuation and future margin profile could depend on how one relatively quiet shift in melanoma treatment preferences unfolds.
That quiet shift in treatment preferences is exactly where Immunocore could surprise, and the full narrative for Immunocore Holdings shows how melanoma trends might be masking upside in this story.
Seeking Alternatives Before The Crowd?
Fresh ideas often move first. By the time momentum is obvious, the most attractive entry points may already have passed. Scan these curated shortlists while they are still under the radar for now, then decide whether they fit your strategy.
-
Review 28 high quality undervalued stocks to explore potential early-stage turnarounds that combine strong cash generation with resilient balance sheets before momentum traders begin to focus on them.
-
Scan 91 robotics and automation stocks to follow businesses involved in real-world robotics, sensors, and industrial systems as adoption patterns develop.
-
Assess 43 power grid technology and infrastructure stocks to examine companies connected to transmission technology, substations, and critical hardware as grid infrastructure continues to evolve.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
